55results about How to "Accurate prognosis" patented technology

The present invention relates to a method for analyzing a genotype using a target-specific nuclease and, specifically, to a method for diagnosing cancer or analyzing a genotype by removing wild type DNA or particular genotype DNA using a target-specific nuclease or a variant thereof to amplify or concentrate only a small amount of DNA which has a difference in variation, such as a mutation, or genotype, and to a method for separating target DNA sesusing a target-specific nuclease or a variant thereof. Such methods are novel paradigm methods contrary to existing simple target-specific nucleases for post-PCR recognition of normal genotype and carcinogenic genotype, and can be favorably used in the early diagnosis of cancer or analysis of similar genotypes.

The present invention relates to the detection of promoter methylation status using a combination of either modification of methylated DNA or restriction endonuclease digestion, multiplex polymerase chain reaction, ligase detection reaction, and a universal array or capillary electrophoresis detection.

A method of optimising a model Mx suitable for use in data analysis and determining a prognostic outcome specific to a particular subject (input vector x), the subject comprising a number of variable features in relation to a scenario of interest for which there is a global dataset D of samples also having the same features relating to the scenario, and for which the outcome is known is disclosed. In one implementation, the method includes: (a) determining what number and a subset Vx of variable features will be used in assessing the outcome for the input vector x; (b) determining what number Kx of samples from within the global data set D will form a neighbourhood about x; (c) selecting suitable Kx samples from the global data set which have the variable features that most closely accord to the variable features of the particular subject x to form the neighbourhood Dx; (d) ranking the Vx variable features within the neighbourhood Dx in order of importance to the outcome of vector x and obtaining a weight vector Wx for all variable features Vx; (e) creating a prognostic model Mx, having a set of model parameters Px and the other parameters from (a)-(d); (f) testing the accuracy of the model Mx at e) for each sample from Dx; (g) storing both the accuracy from (f), and the model parameters developed in (a) to (e); (h) repeating (a) and / or (b) whilst applying an optimisation procedure to optimise Vx and / or Kx, to determine their optimal values, before repeating (c)-(h) until maximum accuracy at (f) is achieved.

An agricultural harvesting machine includes different working units, an input and display unit, a memory and evaluation unit, and a control device for influencing adjustable operating parameters of the working units, at least one set criterium being stored in the memory and evaluation unit, and, based on at least one crop material parameter and / or operating parameter that was determined in the harvesting process, and based on the at least one set criterium, a prognosis regarding the attainability of an actual harvesting goal is formulated, the prognosis being taken into account in the adjustment of the operating parameters.

The invention provides methods of estimating the likelihood of lung cancer recurrence in a subject, including those afflicted with NSCLC. The methods of the invention are useful for developing a therapeutic treatment plan to prevent cancer recurrence for subjects deemed to be at high risk, and withholding treatments from those subjects deemed to be at low risk. The invention also provides methods of generating and using metagene-based prediction tree models for estimating the likelihood of lung cancer recurrence. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for estimating cancer recurrence, and provides methods of conducting a diagnostic business for the prediction of cancer recurrence.

The present invention relates to the detection of promoter methylation status using a combination of either modification of methylated DNA or restriction endonuclease digestion, multiplex polymerase chain reaction, ligase detection reaction, and a universal array or capillary electrophoresis detection.

A method, computer system, and computer memory medium optimizing a transductive model Mx suitable for use in data analysis and for determining a prognostic outcome specific to a particular subject are disclosed. The particular subject may be represented by an input vector, which includes a number of variable features in relation to a scenario of interest. Samples from a global dataset D also having the same features relating to the scenario and for which the outcome is known are determined. In an embodiment, a subset of the variable features within a neighborhood formed by the samples are ranked in order of importance to an outcome. The prognostic transductive model is then created based, at least in part, on the subset, the ranking, and the neighborhood. The subset and the neighborhood are then optimized until the accuracy of the transductive model is maximized.

A novel classification system for breast cancer based on normal breast cell phenotypes and various expression levels of estrogen receptor (ER), androgen receptor (AR), and vitamin D receptor (VDR). The various categories of the classification system are associated with different survival rates and prognoses. The invention includes a method of classifying breast cancer comprises measuring the levels of ER, AR, and VDR in the cancerous tissue, and classifying the breast cancer into one of the above-noted categories according to expression levels. The invention includes a method of predicting the prognosis of breast cancer in a patient and a method of determining a treatment regimen for breast cancer depending on the category in which the breast cancer is classified. The invention includes a method of treating breast cancer according to the expression profile of ER, AR, and VDR detected in the cancerous tissue. Kits for detecting the same are also provided.

By means of a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MAT1A− / −) have been identified for the MAT1A gene (deficient in the synthesis of S-adenosylmethionine). 27 proteins have been detected the expression thereof is altered in, at least, 50% of the analysed tumours. Amongst them, 13 proteins have been validated in biopsies of patients with HCC of different etiology, and 7 of them have been validated in biopsies of patients with liver cirrhosis, a stage prior to the development of HCC, which makes it possible to differentiate between prior stages of the disease and even between different etiologies (viral and alcoholic). Having a panel of markers available may contribute to more accurately defining the alterations associated with the development of HCC and thus facilitate prognosis and diagnosis of this disease.

Disclosed are systems, media, and methods for providing a genomic search engine application comprising: a plurality of indices, recorded in the computer storage, the indices comprising tokenized genomic data; a software module providing an indexing pipeline, the indexing pipeline ingesting genomic data and annotation associated with the genomic data, tokenizing the data while preserving gene names and gene variant names, and updating the indices with the tokenized data; and a software module presenting a user interface allowing a user to enter a user query; a software module providing a query engine, the query engine accepting the user query, selecting one or more relevant indices, and applying a ranking formula to the selected indices to return ranked results.

At least one embodiment relates to an image analysis system for tumor classification. The system is configured for receiving at least one digital image of a tissue sample; analyzing the at least one received image for identifying immune cells and tumor cells in the at least one received image; for each of the identified tumor cells, determining the distance of the tumor cell to the nearest immune cell; computing a proximity measure as a function of the determined distances; in dependence on the proximity measure, classifying the identified tumor cells into tumor cells of an inflammatory tumor or as tumor cells of a non-inflammatory tumor; and storing the classification result on a storage medium and / or displaying the classification result on a display device.

The present invention relates to a method for early prediction of a prostate cancer patient's response to hormonal treatment. In one embodiment, the method of the present invention involves assaying a body fluid, such as plasma or serum, from a prostate cancer patient for the presence of elevated levels of chromogranin A (CgA). Elevated levels of CgA may indicate neuroendocrine differentiation of cells within the prostate tumor, and may require altering the patient's treatment. In a further embodiment of the method of the present invention, periodic assays for CgA are conducted for a patient undergoing hormonal treatment for prostate cancer. The results of these assays are correlated to determine if the patient's levels of CgA are high (greater than 100 ng / mL) or increasing. Such assays may also be carried out in conjunction with assays for total prostate specific antigen (tPSA).

A method for predicting whether a patient suffering from a prostate cancer is at risk of experiencing a cancer progression or recurrence which comprises the steps of : obtaining a Gleason score of said prostate tumor sample; assessing the proportion of NF-kB localized in the nuclei of said tumor sample with regard to all NF-kB present in said tumor sample.

Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.

The invention belongs to the technical field of detection kits, and particularly relates to a kit for aided-diagnosis and prognostic evaluation on glioblastoma based on a gene CLCF1 and a use method thereof. The kit comprises a PCR (polymerase chain reaction) primer pair for amplifying the gene CLCF1 and a PCR primer pair for amplifying a housekeeping gene GAPDH. The kit has the advantages that the obvious difference of the gene CLCF1 in transcription expression levels of LGG (brain lower grade glioma) and GBM (glioblastoma multiforme) is found for the first time, the prognostic condition of apatient with the glioblastoma is well judged by the expression level of the gene CLCF1, and the gene CLCF1 can be used as the index for independently judging the prognostic condition of the glioblastoma after determining by Cox multi-factor regression analysis; after the expression condition of the transcription level of the gene CLCF1 is detected, the severity of the glioblastoma can be diagnosed, and the prognostic condition of the patient can be predicted.

The invention belongs to the technical field of detection kits, and particularly relates to a kit for aided-diagnosis and prognostic evaluation on non-small cell lung cancer based on a gene GALNT2 anda use method thereof. The kit comprises a PCR (polymerase chain reaction) primer pair for amplifying the gene GALNT2 and a PCR primer pair for amplifying a housekeeping gene GAPDH. The kit has the advantages that the obvious difference of the gene GALNT2 in transcription expression levels of non-small cell lung cancer and normal paracancerous tissue is found for the first time, the prognostic condition of a patient with the non-small cell lung cancer is well judged by the expression level of the gene GALNT2, and the gene GALNT2 can be used as the index for independently judging the prognosticcondition of the non-small cell lung cancer after determining by Cox multi-factor regression analysis; after the expression condition of the transcription level of the gene GALNT2 is detected, the non-small cell lung cancer can be diagnosed, and the prognostic condition of the patient can be predicted.

The present invention concerns particular biomarkers for diagnosing and / or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG.

The invention belongs to the technical field of biology, and particularly relates to a gene mutation site group of NK / T cell lymphoma and a kit and application thereof. The invention provides a gene mutation site group of NK / T cell lymphoma, which can be used for evaluating molecular typing of NK / T cell lymphoma, predicting prognosis of a patient and guiding medication of the patient. According tothe kit, an IlluminaMiseq sequencing platform and performance sequencing are adopted, a series of mutant genes related to NK / TCL diseases can be efficiently and accurately detected, the detection period is short, the detection cost is low, the application range is wide, and the accuracy is high.

Disclosed is a method for predicting cancer prognosis, comprising: forming gene pairs by using a plurality of genes to be tested; determining clusters for the formed gene pairs through a clustering method; calculating a distribution of each gene pair based on the determined cluster; and selecting reference gene pairs for determining a class based on the calculated distribution.

Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.

A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.

The invention relates to a method and device for determining a fault of a barometric pressure measuring system arranged aboard a flying device. The method comprises the following steps: determining a current position POSGNSS(t) and an altitude zGNSS(t) of the flying device in a geodetic reference system at a point in time t using a satellite navigation system GNSS arranged aboard a flying device; determining a static pressure pAC(t) and / or a pressure level zAC(t) for the position POSGNSS(t) in provided weather analysis data ANDAT or in provided weather prognosis data PROGDAT of a numerical weather prediction model (NWP) using the pressure measuring system; determining a geopotential altitude ZAN / PROG(t) assigned to the static pressure pAC(t) for the position POSGNSS(t) in provided weather analysis data ANDAT or in provided weather prognosis data PROGDAT of a numerical weather prediction model (NWP); determining a static pressure pAN / PROG(t) assigned to the altitude zGNSS(t); determining the altitude deviation Δz(t)=zGNSS(t)−zAN / PROG(t) and / or determining the pressure deviation Δp(t)=pAC(t)−pAN / PROG(t); determining an altitude deviation Δz* averaged over a period of time Δt from Δz(t)=zGNSS(t)−zAN / PROG(t) and / or a pressure deviation Δp* averaged over a period of time Δt from Δp(t)=pAC(t)−pAN / PROG(t), wherein a fault of the pressure measuring system is deemed detected if the determined averaged altitude deviation |Δz*| is greater than or equal to a specified threshold G1, or if the averaged pressure deviation |Δp*| is greater than or equal to a specified threshold G2; and generating a warning signal if a fault is detected.

The invention belongs to the technical field of detection kits, and in particular relates to a glioblastoma auxiliary diagnosis and prognostic evaluation kit based on an FUCA1 gene and use method of the kit. The kit comprises a PCR (Polymerase Chain Reaction) primer pair for amplifying an FUCA1 gene and a PCR primer pair for amplifying a housekeeping gene GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase). According to the kit, the condition that FUCA1 gene has remarkably different transcription expression levels in LGG and GBM for the first time, meanwhile prognosis of a patient suffering from glioblastoma can be easily judged according to expression levels of the FUCA1 gene, and multi-factor regression analysis of Cox confirms that the FUCA1 gene can be used as an index of independent judgment prognosis of the glioblastoma. Namely, by detecting expression of the FUCA1 gene transcription level, the malignancy grade of a glioma patient can be diagnosed, and the prognosis situation of the patient can be predicted.

The invention discloses an internal reference substance for detecting bladder cancer serum miRNA. The internal reference substance is single hsa-miR-193a-5p or a mixture of hsa-miR-193a-5p and hsa-miR-16-5p. The invention also discloses detection primers of the internal reference substance. The detection primers comprises primers for detecting hsa-miR-193a-5p (shown in the formulas of SEQ ID NO: 1-3) or / and hsa-miR-16-5p (shown in the formulas of SEQ ID NO: 4-6). The internal reference substance and the detection primers can be used for preparation of a kit for detecting a bladder cancer serum internal reference substance and for detection on the bladder cancer serum miRNA internal reference.

Methods for determining various oncogenic-related indexes of patient specific mutations are provided. The methods provided allow determination and grading of various patient specific mutations and qualitative and quantitative determination of various related oncogenic indexes.

The invention belongs to the technical field of detection kits, and particularly relates to an auxiliary glioblastoma diagnosis and prognostic evaluation kit based on an IFI30 gene and a using method thereof. The kit comprises a PCR primer pair which amplifies the IFI30 gene and a PCR primer pair which amplifies a housekeeping gene GAPDH. The kit firstly discovers that the IFI30 gene has obvious difference on the transcriptional expression level in LGG and GBM, meanwhile the expression level of the IFI30 gene can well judge the prognosis of a glioblastoma patient, and the index, which can be used for independently judging the prognosis of glioblastoma, of the IFI300 gene is determined through a Cox multi-factor regression analysis, that is, the expression condition of the IFI300 gene transcriptional level is detected so that the kit can diagnose the malignant degree of the glioblastoma patient and predict the prognosis condition of the patient.

The invention relates to a long non-coding RNA BDNF-AS and application thereof in preparing a product for diagnosing tumors or judging prognosis conditions of breast cancer treatment or judging drug resistance of breast cancer endocrine treatment or treating tumors. The BDNF-AS is taken as a marker, whether breast cancer cells in a sample are resistant to drugs and the prognosis condition of breast cancer can be judged by detecting the expression level of the BDNF-AS in the sample, so that a more effective treatment method is implemented based on a judgment result, the treatment effect is improved, and more side effects caused by blind dosage are avoided. Meanwhile, the long non-coding RNA BDNF-AS can also be used as a treatment target, and the sensitivity of endocrine treatment of the drug-resistant breast cancer to an endocrine treatment drug can be improved by knocking down the BDNF-AS, so that the treatment effect of the drug is improved; the tumor growth can be directly inhibited by singly knocking down the BDNF-AS, so that the BDNF-AS can be combined with other endocrine treatment medicines to realize a synergistic treatment effect.

A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.

The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or a functional fragment thereof, wherein said VHH or a functional fragment thereof specifically binds to a target protein that is present on and / or specific for a solid tumor, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and / or host cells. The application further provides such polypeptides, nucleic acids, host cells and / or compositions, for use in methods for detection, imaging, prognosis and diagnosis of cancer as well as for predicting patient response(s) to therapeutics.